Active, not recruitingPhase 3NCT03866499

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

Studying Catastrophic antiphospholipid syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beta Pharma Shanghai
Principal Investigator
Yuankai Shi
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Intervention
BPI-7711(drug)
Enrollment
369 enrolled
Eligibility
18 years · All sexes
Timeline
20212025

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03866499 on ClinicalTrials.gov

Other trials for Catastrophic antiphospholipid syndrome

Additional recruiting or active studies for the same condition.

See all trials for Catastrophic antiphospholipid syndrome

← Back to all trials